ArticleTherapeutic delivery2025
Design, development, and evaluation of magnetic nanoparticles and docetaxel-loaded nanosystem for brain targeting.
Article in Therapeutic delivery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe study aimed to investigate superparamagnetic iron oxide nanoparticles (SPIONs) as carriers for brain-targeted delivery of the anticancer drug docetaxel (DTX). The use of an externally positioned magnet was explored to achieve targeted delivery to specific regions of interest, enhancing SPIONs' accumulation and retention within the brain.
methodsSPIONs were synthesized using the co-precipitation method. Docetaxel-loaded SPION-PLGA nanoparticles (G-SPIO/DTX-PLGA-NPs) were subsequently prepared using a solvent evaporation process and further coated with glutathione (GSH) to enhance brain targeting in male Wistar rats.
resultsThe G-SPIO/DTX-PLGA-NPs demonstrated a particle size of 190 ± 5.11 nm and a zeta potential of -27.6 ± 0.36 mV. Drug release studies indicated an initial burst release of 15.03 ± 2.33% at 1 h and a sustained release of 78.78 ± 3.50% at 96 h. Cytotoxicity studies revealed significantly higher cell death (84.71%) with the G-SPIO/DTX-PLGA-NPs compared to DTX alone (72.29%), with a 3.39-fold (
conclusionThe study established G-SPIO/DTX-PLGA-NPs as effective SPION-based carriers for targeted docetaxel delivery to the brain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.